NLRP3 and colitis: In conclusion, the current study indicated that oral administration of DP could alleviate the severity of DSS‐induced colitis, and the protection mechanisms might be related to its antioxidant and anti‐inflammation ability via the inhibition of NF‐κB signaling and the NLRP3 inflammasome, as well as the activation of the Nrf2 pathway (Figure 7).